ViewPoints Interview: Medicenna’s Dr. Fahar Merchant Shares Insights on the Bispecific Superkines

In an interview with PharmaShots, Dr. Fahar Merchant, CEO of Medicenna shares his views on the data of a new type of interleukin called bispecific Superkines, presented at AACR 2021   Shots: Bispecific Superkines can attack cold tumors, weakening the protection given to it by the tumor microenvironment and revealing it to the immune system …

ViewPoints Interview: Medicenna’s Dr. Fahar Merchant Shares Insights on the Bispecific Superkines Read More »